Endometrial Ablation Devices Global Market Report 2024

The endometrial ablation devices market size has grown strongly in recent years. It will grow from $3.52 billion in 2023 to $3.77 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth observed in the historical period can be credited to shifts in attitudes regarding women's health, an increased prevalence of abnormal uterine bleeding, a growing demand for alternatives to hysterectomy, and a noticeable transition towards outpatient treatment procedures.

The endometrial ablation devices market size is expected to see strong growth in the next few years. It will grow to $4.8 billion in 2028 at a compound annual growth rate (CAGR) of 6.2%. The anticipated growth in the upcoming period can be linked to heightened awareness and education regarding women's health, a significant focus on fertility preservation, an increased emphasis on personalized medicine approaches, supportive regulatory measures and guidelines, and an enhanced focus on office-based procedures. Key trends expected in this period involve the incorporation of telemedicine and remote consultations, the standardization of protocols, a shift towards non-hormonal treatment options, the integration of patient-centric care, and the development of safer procedures.

The growth of the endometrial ablation devices market is anticipated to be fueled by the increasing prevalence of gynecological disorders. Gynecological disorders encompass various medical conditions affecting the female reproductive system, including menstrual disorders, endometriosis, polycystic ovary syndrome (PCOS), uterine fibroids, pelvic inflammatory disease (PID), and ovarian cysts. Endometrial ablation devices play a crucial role in treating these disorders by destroying the endometrial lining, providing relief from heavy menstrual bleeding, and addressing conditions such as adenomyosis and endometrial hyperplasia. As of June 2023, the World Health Organization reports that PCOS affects 8–13% of reproductive-aged women, with up to 70% of affected women globally going misidentified. This increasing prevalence underscores the driving force behind the growth of the endometrial ablation devices market.

The endometrial ablation devices market is poised for growth due to the rise in healthcare spending. Healthcare expenditure refers to the total financial resources allocated for healthcare services, goods, and infrastructure within specific regions or organizations. The allocation of resources to efficient and targeted healthcare spending enhances the overall connectivity, safety, and effectiveness of endometrial ablation procedures, leading to improved outcomes for women with gynecological disorders. As of September 2022, the Centers for Medicare & Medicaid Services in the United States projects a 2.7% increase in national health spending, reaching $4.3 trillion in 2021. This corresponds to $12,914 per person and 18.3% of the country's GDP. The upward trajectory in healthcare spending underscores its role in driving the growth of the endometrial ablation devices market.

Product innovation stands out as a prominent trend in the endometrial ablation devices market, with major companies strategically focusing on developing inventive solutions. In November 2021, Hologic, Inc., a leading US-based health technology company, introduced the NovaSure V5 endometrial ablation device. This advanced global endometrial ablation (GEA) device addresses abnormal uterine bleeding in women by employing radiofrequency energy to ablate the endometrial lining. The NovaSure V5 incorporates technological features such as sure clear technology, end form technology, and smart depth technology, enhancing its efficacy and providing a more comfortable and effective treatment option for women experiencing abnormal uterine bleeding.

Major companies in the endometrial ablation devices market are driving innovation through the development of advanced solutions, including incisionless systems for radiofrequency ablation of fibroids. These systems integrate real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in a minimally invasive procedure, presenting an alternative to traditional surgical interventions such as hysterectomy and myomectomy. For instance, in September 2021, Gynesonics, a US-based women's health diagnostics and therapeutic technology company, received FDA approval for the Sonata System 2.2. This updated system offers a 20% reduction in the smallest ablation size setting, improved maneuverability for fibroids in tighter locations, and innovative software developments that empower surgeons to control all aspects of the ablation directly from the handpiece, streamlining procedures and benefiting facilities, clinicians, and patients alike.

In February 2021, CooperSurgical Inc., a US-based healthcare firm, completed the acquisition of AEGEA Medical Inc. This strategic move was executed to broaden CooperSurgical's range of women's health products. The acquisition grants CooperSurgical access to AEGEA Medical's innovative sure clear technology, strengthening its market presence and capability to offer advanced solutions to address various women's healthcare requirements. AEGEA Medical Inc. is a medical device manufacturing company based in the US, specializing in the development of endometrial ablation procedural devices and other products aimed at addressing menstrual bleeding concerns.

Major companies operating in the endometrial ablation devices market report are Johnson and Johnson Private Limited, Medtronic Plc., Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Smith And Nephew plc., Hologic Inc., C R.Bard Inc., Cooper Companies Inc., Cook Medical, Karl Storz GmbH And Co. KG, Biotronik SE And Co. KG, B. Braun Medical Inc., Richard Wolf GmbH, Aesculap Inc., AngioDynamics, Gyrus ACMI Inc., Minerva Surgical Inc., Minerva Surgical Inc., Lina Medical ApS, Biolitec AG, AEGEA Medical Inc., Albyn Medical,Channel Medsystems Inc., CathRX Ltd, Ecleris Srl., Idoman Teoranta, Surkon Medical Co. Ltd, Omnitech Systems Inc., Veldana Medical SA.

North America was the largest region in the endometrial ablation devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the endometrial ablation devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the endometrial ablation devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The various categories of endometrial ablation devices exist, including hysteroscopy devices, thermal balloon ablators, radiofrequency endometrial ablation devices, hydrothermal ablators, electrical ablators, and others. Hysteroscopy devices encompass a suite of medical tools employed in the diagnostic and therapeutic practice of hysteroscopy. These technologies, comprising radiofrequency ablation, cryoablation, hydrothermal ablation, thermal balloon procedures, and hysteroscopic ablation, cater to diverse end-users such as ambulatory surgery centers, clinics, and hospitals.

The endometrial ablation devices market research report is one of a series of new reports that provides endometrial ablation devices market statistics, including endometrial ablation devices industry global market size, regional shares, competitors with an endometrial ablation devices market share, detailed endometrial ablation devices market segments, market trends and opportunities, and any further data you may need to thrive in the endometrial ablation devices industry. This endometrial ablation devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The endometrial ablation devices market consists of sales of radiofrequency ablation devices, cryoablation devices, hydrothermal devices, and microwave ablation devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.